Recent

% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • kevinmik kevinmik Jun 18, 2013 6:36 PM Flag

    Pfizer Has The Money To Outbid The Competition For Afrezza

    I expect Pfizer is salivating about getting a second opportunity to get their hands on the only approved inhaled insulin drug that will ultimately capture a huge share of the overall diabetes market including Type I, Insulin Using Type II and early Type II. Pfizer knows Exubera had a lot of flaws and they also know that Afrezza has none of those flaws and is actually going to be the best insulin, best diabetes drug in the market. I think the other major players are Sanofi-Aventis, Novo and Medtronic, but none of these company's have the cash to compete with Pfizer. What Pfizer wants, Pfizer gets..................

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MNKD
0.609-0.006(-1.02%)Sep 28 4:00 PMEDT